Oxford Biomedica PLC Director/PDMR Shareholding (6138X)

TIDMOXB

RNS Number : 6138X

Oxford Biomedica PLC

13 August 2018

PDMR Dealings / Market Share Sale

Oxford, UK - 13 August 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 09 August 2018 James Miskin, Chief Technical Officer, exercised 11,759 options at 50p, exercised 500 options at 287.5p and 814 options at 141.5p and sold all of the resulting shares at 904.416p.

Following this transaction he holds 163,272 options and no shares in the company.

The issued share capital of the Company is 65,752,788 ordinary shares of 50 pence each.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                           James Miskin 
     -----------------------------  ----------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------ 
 a)   Position/status                Chief Technical Officer 
     -----------------------------  ----------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
     -----------------------------  ----------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------ 
 a)   Name                           Oxford BioMedica plc 
     -----------------------------  ----------------------------------- 
 b)   LEI code                       213800S1GVQNXQ15K851 
     -----------------------------  ----------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------ 
 a)   Description of                 Ordinary Shares of 50 pence each 
       the financial                  ISIN: GB00BDFBVT43 
       instrument 
       Identification 
       code 
     -----------------------------  ----------------------------------- 
 b)   Nature of the                  Exercise of options 
       transaction 
     -----------------------------  ----------------------------------- 
 c)   Currency                       GBP - British pound 
     -----------------------------  ----------------------------------- 
 d)   Price(s) and volumes(s)          Price(s)    Volume(s) 
                                        GBP0.500    11,759 
                                                   ---------- 
                                        GBP2.875    500 
                                                   ---------- 
                                        GBP1.415    814 
                                                   ---------- 
     -----------------------------  ----------------------------------- 
 e)        Aggregated information     13,073 
             *    Aggregate volume     GBP0.648 
                                       GBP8,468.81 
 
 
             *    Price 
 
 
 
             *    Aggregated total 
     -----------------------------  ----------------------------------- 
 f)   Date of the transaction        2018-08-09 
     -----------------------------  ----------------------------------- 
 g)   Place of the transaction       London Stock Exchange, Main Market 
                                      (XLON) 
     -----------------------------  ----------------------------------- 
 
 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                           James Miskin 
     -----------------------------  ----------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------ 
 a)   Position/status                Chief Business Officer 
     -----------------------------  ----------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
     -----------------------------  ----------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------ 
 a)   Name                           Oxford BioMedica plc 
     -----------------------------  ----------------------------------- 
 b)   LEI code                       213800S1GVQNXQ15K851 
     -----------------------------  ----------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------ 
 a)   Description of                 Ordinary Shares of 50 pence each 
       the financial                  ISIN: GB00BDFBVT43 
       instrument 
       Identification 
       code 
     -----------------------------  ----------------------------------- 
 b)   Nature of the                  Disposal 
       transaction 
     -----------------------------  ----------------------------------- 
 c)   Currency                       GBP - British pound 
     -----------------------------  ----------------------------------- 
 d)   Price(s) and volumes(s)          Price(s)      Volume(s) 
                                        GBP9.04416    13,073 
                                                     ---------- 
     -----------------------------  ----------------------------------- 
 e)        Aggregated information     13,073 
             *    Aggregate volume     GBP9.04416 
                                       GBP118,234.30 
 
 
             *    Price 
 
 
 
             *    Aggregated total 
     -----------------------------  ----------------------------------- 
 f)   Date of the transaction        2018-08-09 
     -----------------------------  ----------------------------------- 
 g)   Place of the transaction       London Stock Exchange, Main Market 
                                      (XLON) 
     -----------------------------  ----------------------------------- 
 

-Ends-

 
 For further information, please contact: 
  Oxford BioMedica plc:                       Tel: [phone] 
   John Dawson, Chief Executive Officer 
   Stuart Paynter, Chief Financial Officer 
  Financial and corporate communications      Tel: [phone] 
   enquiries: 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew Neal/Olivia 
   Manser/Laura Thornton 
 

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHGCGDIGUBBGIX

(END) Dow Jones Newswires

August 13, 2018 05:55 ET (09:55 GMT)